Tango reports 82% response rate for vopimetostat-daraxonrasib combo in pancreatic cancer
Tango plans a Phase 3 trial starting in the first half of 2027 after FDA discussions on the PRMT5 inhibitor paired with Revolution Medicines' RAS(ON) drug.
Tango Therapeutics announced updated results on October 23, 2026 from its ongoing Phase 1/2 study combining vopimetostat, its investigational PRMT5 inhibitor, with Revolution Medicines' RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant pancreatic and lung cancers, presented at the ESMO 2026 Congress in Madrid.
Using an August 20, 2026 data cutoff, the study showed an 82% objective response rate, with median progression-free survival not yet reached and a 9-month PFS rate of 88%, among 22 efficacy-evaluable patients with second-line or third-line MTAP-deleted, RAS-mutant pancreatic cancer.1 Most of those evaluable patients, 13 of 22, had received the combination as a third-line treatment.1
At the primary dose level, the daraxonrasib combination was tolerated with no dose-limiting toxicities and no treatment discontinuations from side effects; the rate of Grade 3 treatment-related adverse events was 40% (10/25), with the most common being stomatitis (48%), rash (44%), and diarrhea (28%), all Grade 1-2.1 A higher dose level was not well tolerated, with three dose-limiting toxicities in two patients.1
In a separate arm combining vopimetostat with zoldonrasib, another RAS(ON) inhibitor, the company reported a 54% objective response rate, a 61% 9-month PFS rate, and a 97% disease control rate across 35 evaluable patients, with generally tolerable safety.1
Following FDA discussions, Tango plans to initiate a global, randomized registrational trial of vopimetostat plus daraxonrasib in front-line MTAP-deleted pancreatic cancer patients in the first half of 2027.1 The trial will randomize patients 1:1 between the combination and standard chemotherapy, with dual primary endpoints of response rate and progression-free survival and overall survival as a key secondary endpoint.1
Separately, Tango's board approved a strategic reprioritization on October 22, 2026, focusing resources on vopimetostat and TNG456 while cutting its workforce by approximately 14%, mostly in research.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.